Around the Asia-Pacific, the knee biomaterial market is changing a lot. This shows that the healthcare system in that area is also changing. Here are some important market tips:
Joint discomfort is rising throughout Asia-Pacific. This is usually due to longer lifespans, lifestyle changes, and more sports injuries. As more individuals have bone and muscular problems, these polymers become increasingly significant. They are vital for osteoarthritis and fractured bone procedures.
New biomaterial options are always coming out to keep the market fresh. With some of these innovations, new materials are made that are better for living things and last longer. It is being researched and worked on how to make nanomaterials, such as metals, clay, and plastics, act like living cells. This means they will fit better inside the body, which will make the effects even better for the patient.
In the Asia-Pacific area, the orthopedic biomaterial market is mostly driven by treatments that rebuild joints, such as hip and knee implants. People are living longer and having more joint problems, so the need for biomaterials used in repair surgeries is growing. This trend is likely to keep going since making life better for people with joint problems is getting more and more attention.
Orthobiologics is becoming more and more popular. People use cells that come from either their own bodies or from environmental sources. People do this because they want cells to grow back more quickly and with less chance of being rejected. In Asia-Pacific, orthopedic therapies are increasingly using PRP and stem cell-based technologies.
Broken joints and spine surgery are using different surgical implants, altering the demand for high-quality plastics. Biomaterials that persist, work with living things, and perform effectively are crucial to hip implant success. This market always seeks improvements to expand.
Most Asian-Pacific residents over 60 have osteoporosis. As osteoporosis diagnoses rise, bone transplants and other strengthening procedures need more metals. In general, this article discusses bone and joint health concerns.
Asia-Pacific is increasingly becoming a medical hub. People seeking affordable medical treatment go to India, Thailand, and Malaysia. Patients and clinicians want to employ cutting-edge materials and technology in joint therapies, therefore high-quality biomaterials are needed.
Asia-Pacific medical plastics regulations are becoming more standardized. When there are many restrictions, market participants must conduct their firms the same manner and meet foreign quality and safety standards. Now that the criteria are same, acceptance should be simple. It will boost the market.
Market companies are investing more in R&D to keep ahead of the competition and fulfill healthcare industry demands. Investing in better, novel, and world-changing medical biomaterials is crucial due to the growing demand for them.
Being environmentally friendly is becoming increasingly crucial as the medical plastics business increases. People want eco-friendly products and methods to reduce their environmental effect. Healthcare workers are becoming more conscious of how their decisions influence people worldwide. Sustainability issues become increasingly essential.
Asia Pacific Orthopedic Biometrial Market Size was valued at USD 22.67 Billion in 2023. The Asia Pacific Orthopedic Biometrial industry is projected to grow from USD 23.88 Billion in 2024 to USD 42.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.64% during the forecast period (2024 - 2032). Orthopedic biomaterials are organic or synthetic materials used for the treatment of internal fractures. During the last decade different new techniques and materials are introduced for orthopedic implants and surgeries and biomaterials have found a vital role in it.
These biomaterials are used in manufacturing of different implants since they do not evoke any immunological reactions with the body, which makes it a first choice for manufacturing of implants. Increasing demand for the orthopedic biomaterial because of its application in knee and hip replacement surgeries, and increasing incident of medical emergencies drive the Asia Pacific orthopedic biomaterial market.
Introduction of novel implants of titanium has increased the success rate of implant surgeries and also contributed to the growth of the orthopedic market in Asia Pacific. Moreover, increasing number of orthopedic surgeries, increasing aging population, and growing governmental support also drive the Asia Pacific market. However, increasing failure in joints implants, stringent regulatory laws, and high cost of treatment may hinder the growth of Asia Pacific orthopedic biomaterial market during the review period.
Orthopedic biomaterials might be artificial or natural. They are made to be inserted into a person's body as parts of machines that are intended to carry out certain biological tasks by replacing or mending various tissues. Orthopedic biomaterials are utilized for tissue fixation, spine implants, joint replacements, and other orthopedic procedures. Additionally, the need for next-generation orthopedic biomaterials specifically designed to fulfill the requirements of a particular orthopedic operation is on the rise globally. On the other hand, the market's expansion has been hampered by the restricted payment coverage alternatives for these devices and the falling reimbursement for orthopedic implants in several nations. Additionally, the lack of rebates has forced suppliers to reduce the cost of these products, which has slowed market expansion.
The growing geriatric population, rising incidence rates of accidents and sports-related injuries, rising awareness of orthopedic biomaterials, and introduction of novel products by major market players are a few of the factors anticipated to boost market growth over the forecast period. Fewer traffic accidents and injuries occurred due to the pandemic's widespread lockdowns, curtailing private and public transit. As a result, the focus of healthcare institutions shifted from operations to COVID-19 patients. This immediately affected the market during the early pandemic phase, especially in specialist hospitals. Increased bone fractures, disc degenerative disorders, and more trauma cases are predicted to increase product demand in this market. Due to factors like the rising geriatric population, increasing incidence rates of accidents and sports-related injuries, and rising awareness of orthopedic biomaterials.
CitrefixTM, a suture anchor system for surgical procedures on the foot and ankle, was introduced by Stryker. The new technology uses CitregenTM, a highly acclaimed bioresorbable substance created to imitate the composition and structure of natural bone. Citrefix is a resorbable, bio-inspired suture anchor system for single-use sutures. Citregen, an elastomeric substance formed from a citrate polymer and specifically created to imitate bone chemistry for regulated resorption without persistent inflammation, is used in its construction. These special chemical and mechanical qualities are intended to promote healthy bone growth and heal transplanted tissue when used in orthopedic surgical procedures.
Some of the major players in Asia Pacific orthopedic biomaterial market:
The orthopedic biomaterials market is segmented on the basis of types of material, applications, and end users. On the basis of types of material, the market is segmented into metals and non-metals. The metals are further segmented into stainless steel, titanium alloy, cobalt alloy, and others. Non-metal are further segmented into ceramic, polymeric, natural biomaterials, and others. The ceramic are sub-segmented into alumina, calcium phosphate, zirconium dioxide, carbon, and others. The polymeric materials are sub-segmented into polymethylmethacrylate (PMMA), polyethylene, silicone, polyester, and other. The natural biomaterials are sub-segmented into collagen, chitin & chitosan, and other
On the basis of applications, the Asia Pacific orthopedic biomaterial market is segmented into joint replacement, fracture fixation devices, tissue fixation, spine implants, viscosupplementation, and other. Joint replacement is sub-segmented into hip replacement, knee replacement, shoulder and elbow replacement, and other. Tissue fixation is sub-segmented into interference screws, suture anchors, and others. Spine implants are further sub-segmented into spine fusion and other. The fracture fixation devices are sub segmented into screws, plates for bones, rods, and other.
On the basis of end users, the Asia Pacific orthopedic biomaterial market is segmented into hospital, clinics, and others.The first surgical application of Acuitive Technologies, Inc.'s (Acuitive) Citrelock® ACL Tendon Fixation Device was disclosed. The novel ACL device offers orthopedic surgeons a unique design thanks to a tendon-friendly spiral thread made of Citregen, a next-generation resorbable material with special molecular and mechanical characteristics. With its cutting-edge material technology and distinctive design, the Citrelock ACL Tendon Fixation Device contributes to meeting this therapeutic requirement. The Citrelock ACL System is an exciting new addition to Acuitive's line of products and the first of many that we will be releasing with an emphasis on the sports medicine sector.
China dominates the Asia Pacific orthopedic biomaterial market owing to increasing prevalence of different orthopedic surgeries in China. Increasing awareness of biodegradable products among the people, rapid research and development and huge aging population in this region have added fuel to the growth of the market. Japan and Australia are other major contributor of the Asia Pacific orthopedic biomaterial market in this region.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)